IHC further showed that, compared with the control, systemic and intranasal administration of LY294002, 3‐MA, and AS605240 significantly reduced the expression of p‐Akt and p‐mTOR in nasal polyps (Figure 2A–D). Here, AKT1 is linked to nasal cavity polyp.